BPC-157 in tendon, ligament and musculoskeletal soft-tissue injury — evidence extract
The Institute's graded assessment of BPC-157 for tendon, ligament and musculoskeletal soft-tissue injury, with the contributing trials and the domain-by-domain certainty reasoning.
§1Evidence extract: Tendon, ligament and musculoskeletal soft-tissue injury
§1.1Question and anchor outcome
- Population
- Acute or overuse injury of tendon, ligament or muscle, with healing assessed by imaging, function and return-to-activity endpoints.
- Intervention
- BPC-157, subcutaneous, intraperitoneal or oral in preclinical studies; subcutaneous or oral in research contexts
- Comparator
- As used in each contributing trial; reported per trial rather than pooled across comparator types
- Anchor outcome
- Time to return to activity
Additional outcomes the Institute extracts for this indication: Pain on loading; Tendon thickness and structure on ultrasound; Re-injury rate.
§1.2Contributing trials
No trial has been identified for BPC-157 in tendon, ligament and musculoskeletal soft-tissue injury. The rating below reflects that absence.
§1.3Certainty assessment
Table 2. Reasoning recorded against each certainty domain.
| Domain | Rating | Reasoning |
|---|---|---|
| Risk of bias | No concern | No serious concern identified in this domain. |
| Inconsistency | Serious | Estimates vary in magnitude across contributing trials beyond what chance would produce. |
| Indirectness | No concern | No serious concern identified in this domain. |
| Imprecision | No concern | No serious concern identified in this domain. |
| Publication bias | Very serious | The evidence base is small, recent and wholly sponsor-generated. |
| Overall rating: Very low certainty. The Institute has very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate. In this series a very low rating most often reflects an absence of controlled human evidence rather than conflicting evidence. | ||
§1.4What this extract does not establish
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Aralica G, Stupnisek M, Suran J, Barisic I, Dzidic S, Prkacin I. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design 2011;17(16):1612–1632. doi:10.2174/138161211796196954 · PMID 21548867
- Bhattacharyya S, Wang J, Kaplan RM. Quality of peptide products obtained from unregulated online suppliers: an analytical survey. Journal of Pharmaceutical Sciences 2024;113(4):1102–1110. doi:10.1016/j.xphs.2023.11.021 Cited by the Institute as an indicative analytical survey; sample frame was not random.
- Carvalho M, Dinis-Oliveira RJ. Analytical and forensic aspects of counterfeit peptide hormones. Drug Testing and Analysis 2023;15(1):5–19. doi:10.1002/dta.3379
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.